Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies to Raise $5.1M in Direct Offering

NEW YORK — Australian molecular diagnostics firm Genetic Technologies said on Thursday that it has signed definitive agreements to sell $5.1 million worth of its American Depositary Shares (ADSs) to institutional investors.

Through the direct offering, the Genetic Technologies will sell 1,025,000 ADSs at $5 apiece. Each ADS, the company said, represents 600 of its ordinary shares. The transactions are expected to close on or around July 20.

HC Wainwright is the exclusive placement agent for the offering.

Genetic Technologies said it will use the proceeds of the offering to support the introduction and distribution of its products in the US; for R&D and reimbursement studies around its polygenic risk tests in collaboration with the Translational Genomics Research Institute; for the implementation of its consumer-initiated testing platform; to prepare for COVID-19 Severity Risk Test; and for working capital and potential acquisitions.

In May, Genetic Technologies priced a public offering of 4,000,000 of its ADSs at $2 each. A month earlier, it signed agreements to offer 722,502 of its ADSs at $2 each.

On Wednesday, Genetic Technologies' ADSs closed on the Nasdaq at $5.67.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.